Bictegravir/emtricitabine/tenofovir alafenamide in adults with <scp>HIV</scp>‐1 and end‐stage kidney disease on chronic haemodialysis
These findings support the use of the once-daily B/F/TAF single-tablet regimen for people with HIV-1 and ESKD on HD. This regimen offers a convenient treatment option for this population as it reduces the need for dose adjustment, eases pill burden and avoids potential drug-drug interactions associated with alternatives that may impact individuals on multiple medications or awaiting transplantation.
Authors
- Aimee Wilkin (ORCID: https://orcid.org/0000-0003-2435-4738)
- Christiana Blair
- Mehri S. McKellar (ORCID: https://orcid.org/0000-0003-2942-5398)
- Priyanka Arora (ORCID: https://orcid.org/0009-0003-8894-892X)
- Joseph J. Eron (ORCID: https://orcid.org/0000-0002-4938-0644)
- Jihad Slim (ORCID: https://orcid.org/0000-0002-4192-7246)
- Moti N. Ramgopal (ORCID: https://orcid.org/0000-0001-7448-1976)
- Jason T. Hindman (ORCID: https://orcid.org/0000-0003-1513-3423)
- Edwin DeJesus
- Olayemi Osiyemi
Institutions
- University of North Carolina at Chapel Hill (US)
- New York Medical College (US)
- Triple O Medical Services (US)
- Orlando Immunology Center (US)
- Duke Medical Center (US)
- Gilead Sciences (United States) (US)
- Wake Forest University (US)
Publication Details
- Journal
- HIV Medicine
- Published
- 2024-10-06
- DOI
- https://doi.org/10.1111/hiv.13721
- Citations
- 2
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.78
Funders
- Gilead Sciences
- University of Warwick